Abstract
Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical utility in oncology. We describe here a fast, flexible and cost-effective method to profile multiple genes simultaneously in low input cell-free DNA (cfDNA): Next Generation-Targeted Amplicon Sequencing (NG-TAS). We designed a panel of 377 amplicons spanning 20 cancer genes and tested the NG-TAS pipeline using cell-free DNA from two HapMap lymphoblastoid cell lines. NG-TAS consistently detected mutations in cfDNA when mutation allele fraction was > 1%. We applied NG-TAS to a clinical cohort of metastatic breast cancer patients, demonstrating its potential in monitoring the disease. The computational pipeline is available at https://github.com/cclab-brca/NGTAS-pipeline.
| Original language | English |
|---|---|
| Article number | 1 |
| Journal | Genome Medicine |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| State | Published - 4 Jan 2019 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019 The Author(s).
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- Computational pipeline
- Deep sequencing
- Heterogeneous
- Liquid biopsy
- Multiplexing
- Mutation
- NG-TAS
- ctDNA
Fingerprint
Dive into the research topics of 'Next Generation-Targeted Amplicon Sequencing (NG-TAS): An optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver